Diagnostic Center of Excellence Team

Driving change in nephrology: PARASOL project leads to FDA acceptance of proteinuria

Designing the Future of Pediatric Rare Disease Trials for Cell and Gene Therapy

Bridging Innovation and Impact: Why Evidence Generation is the New Currency in Biotech

Discover how biotech companies strategically leverage medical evidence generation to demonstrate value, accelerate market access, and drive real-world impact.

Peter M. Neupert

Peter Neupert serves as Fortrea’s Chairman and Interim Chief Executive Officer.

Sustainability in Clinical Trials

How assumptions in protocol design are a root of trial failure: Avoiding “unicorns” in clinical trial protocol design

Accelerate your success with Fortrea’s Site Support Services

NICE technology appraisals of oncology treatments